Carpal tunnel syndrome and trigger finger are two of the most common reasons people search for regenerative options for their hands and wrists, and both involve structures that have become a focus of PRP marketing. The problem is that the newest evidence is not as supportive as the marketing suggests. A 2025 meta-analysis of PRP for carpal tunnel syndrome found only minimal, mostly non-significant effects, and there is still no dedicated meta-analysis for trigger finger. This article sorts through what the 2025 and 2026 research actually shows, and what an honest clinic should tell you.
365
patients pooled across 7 randomized trials in the 2025 carpal tunnel PRP meta-analysis
0
dedicated meta-analyses of PRP for trigger finger as of 2026
3-6
months at which the 2025 carpal tunnel meta-analysis found no difference from controls
Carpal tunnel syndrome happens when the median nerve is compressed as it passes through the wrist, producing tingling, numbness, or weakness in the thumb, index, and middle fingers, often worse at night. Trigger finger, or stenosing tenosynovitis, happens when the tendon sheath of a finger becomes inflamed and the digit catches or locks as it bends. Both are extremely common in Honolulu, from office workers on keyboards to caregivers, musicians, and people who spend hours texting or gripping a paddle or a board.
The most recent pooled evidence came from a meta-analysis published in Medicine in 2025, covering 7 randomized trials and 365 patients. Its findings were sobering: PRP produced only minimal, statistically non-significant effects on the median nerve's cross-sectional area and on distal motor latency, two objective measures of nerve compression. Sensory nerve conduction velocity was actually significantly lower in the PRP group at one month, and by three and six months there was no difference between PRP and control treatment at all. In plain terms, the best current pooled evidence does not support PRP as a reliable treatment for established carpal tunnel syndrome.
“A 2025 meta-analysis of 7 randomized trials and 365 patients found PRP for carpal tunnel syndrome produced only minimal, non-significant effects on nerve measures, with no difference from controls by three to six months.”
The evidence for trigger finger is even thinner. As of 2026 there is no dedicated meta-analysis of PRP for stenosing tenosynovitis. A 2025 narrative review of PRP for hand tendon injuries concluded the treatment is generally safe and may offer some benefit, while noting heterogeneous results and limited gains compared with corticosteroids. The highest-quality ongoing study, a randomized triple-blind trial comparing PRP with corticosteroid and saline injections, has not yet published its results. A broader 2025 meta-analysis of PRP versus corticosteroid for tendinopathy included only two tenosynovitis cases and found no significant group differences. That is simply not enough evidence to present PRP as an established treatment for a locked or catching finger.
This is a case where the most trustworthy advice is often the least exciting. For mild carpal tunnel, conservative care is the well-supported first step: night splinting, activity modification, nerve-gliding exercises, and addressing the underlying strain. For trigger finger, a corticosteroid injection or, when needed, a minor release procedure are the established options, and they work well for many people. PRP may have a future role in hand and wrist care, but the current evidence does not justify presenting it as a reliable replacement for the standard treatments that have decades of data behind them.
A note from the clinic
Our goal at Aloha Stem Cell is to give you straight answers, even when the straight answer is that a treatment is not the right fit. For hand and wrist symptoms we will help you understand what is actually going on and where the honest evidence points, whether that is toward regenerative therapy, conservative care, or a specialist who treats hands and wrists every day. Call (808) 593-2525 or book a consultation to talk through your situation.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.